Overview

Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC

Status:
Terminated
Trial end date:
2019-01-11
Target enrollment:
Participant gender:
Summary
This research study is studying radiation therapy in combination with an immunotherapy as a possible treatment for metastatic hormone receptor (HR) positive, HER2-negative breast cancer. The interventions involved in this study are: - Palliative Radiotherapy - Pembrolizumab
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab